2seventy Bio, Novo Nordisk Expand Partnership to Develop Gene Editing

2seventy Bio, Novo Nordisk Expand Partnership to Develop Gene Editing

315812

2seventy Bio, Novo Nordisk Expand Partnership to Develop Gene Editing

2seventy Bio has expanded its collaboration with Novo Nordisk to develop a gene-editing approach to treat hemophilia A. The new venture adds to an ongoing partnership between 2seventy’s parent company, Bluebird Bio, and Novo Nordisk, which focused on finding new gene therapy candidates. Under this agreement, Novo Nordisk has the option to exclusively license 2seventy Bio’s proprietary mRNA-based megaTAL technology — customizable enzymes designed to recognize and cut specific DNA regions. Recommended Reading December 13,…

You must be logged in to read/download the full post.